Project

ENIGMA: Open label, non-randomized, Phase IB study to character-ize safety, tolerability and recommended dose of EDO-S101, a first-in-class alkylating histone deacetylase inhibition (HDACi) fusion molecule, in combination with Nivolumab in patients with refractory, locally advanced or metastatic melanoma

Ongoing - recruitment closed · 2019 until 2024

Jörger Markus, Wittwer Yvonne, Quinter Janine